Want to see GB:CIZ full AI Analyst Report?
Cizzle Biotechnology Holdings PLC (CIZ) AI Stock Analysis
Cizzle Biotechnology Holdings PLC
(LSE:CIZ)
Weak financial performance from zero revenue, negative equity and cash burn dominates; bearish technicals with price below moving averages add pressure, while negative P/E limits valuation support.
Cizzle Biotechnology Holdings PLC (CIZ) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 4.89M
- Dividend Yield
- ―
- Average Volume (3M)
- 2.03M
- Price to Earnings (P/E)
- -7.2
- Beta (1Y)
- -0.91
- Revenue Growth
- ―
- EPS Growth
- 42.86%
- Country
- UK
- Employees
- 5
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Cizzle Biotechnology Holdings PLC Business Overview & Revenue Model
Company Description
Cizzle Biotechnology Holdings Plc specializes in developing an advanced immunoassay diagnostic test. This innovative tool aims to identify the CIZ1B biomarker, facilitating the early detection of lung cancer. The company, previously known as Cizzle B...
How the Company Makes Money
Cizzle Biotechnology’s primary intended revenue model is to generate income from the commercialization of its lung-cancer diagnostic technology, typically through licensing and/or partnership arrangements with established diagnostics, laboratory, or...
Cizzle Biotechnology Holdings PLC Financial Statement Overview
Summary
No revenue, persistent net losses, negative equity and declining assets in 2025 indicate high insolvency risk, offset partially by zero debt and reduced cash burn.
Income Statement
35NegativeBalance Sheet
15Very NegativeCash Flow
45Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -1,000 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -724.00K | -753.00K | 2 | 0 | -962.04K | -3.96M |
| Net Income | -652.00K | -691.00K | -2,166 | -1,717 | -910.00K | -3.92M |
Balance Sheet | ||||||
| Total Assets | 191.00K | 245.00K | 492.00K | 1.69M | 2.79M | 1.16M |
| Cash, Cash Equivalents and Short-Term Investments | 81.00K | 116.00K | 387.00K | 1.56M | 478.00K | 875.00K |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 528.00K | 585.00K | 410.00K | 186.00K | 145.00K | 218.00K |
| Stockholders Equity | -337.00K | -340.00K | 82.00K | 1.51M | 2.64M | 937.00K |
Cash Flow | ||||||
| Free Cash Flow | -532.00K | -498.00K | -358.00K | -639.00K | -872.00K | -1.21M |
| Operating Cash Flow | -532.00K | -496.00K | -358.00K | -639.00K | -872.00K | -1.01M |
| Investing Cash Flow | 0 | -2,000 | 0 | 0 | -120.00K | -154.00K |
| Financing Cash Flow | 431.00K | 249.00K | 579.00K | 305.00K | 595.00K | 2.03M |
Cizzle Biotechnology Holdings PLC Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:CIZ, the sentiment is Negative. The current price of 1.15 is below the 20-day moving average (MA) of 1.18, below the 50-day MA of 1.39, and below the 200-day MA of 1.96, indicating a bearish trend. The MACD of -0.09 indicates Negative momentum. The RSI at 38.29 is Neutral, neither overbought nor oversold. The STOCH value of 76.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:CIZ.
Cizzle Biotechnology Holdings PLC Peers Comparison
Overall Rating
- GB:CIZ43Neutral
GB:FUM42Neutral
GB:TCF42Neutral
GB:VAL42Neutral
GB:OPTI41Neutral
GB:NFX39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| GB:CIZ | 43Neutral | GBP 5.52M | -7.19 | 192.61% | ― | ― | 42.86% |
| GB:FUM | 42Neutral | GBP 2.59M | -0.29 | -152.41% | ― | -70.77% | 60.39% |
| GB:TCF | 42Neutral | GBP 4.64M | -1.70 | -93.92% | ― | ― | 55.56% |
| GB:VAL | 42Neutral | GBP 2.24M | -0.89 | -71.49% | ― | -34.36% | 57.45% |
| GB:OPTI | 41Neutral | GBP 5.99M | -1.35 | -77.85% | ― | 11.90% | -2864.29% |
| GB:NFX | 39Underperform | GBP 2.79M | -2.12 | -83.53% | ― | ― | 93.02% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:CIZ | Cizzle Biotechnology Holdings PLC | 1.15 | -0.60 | -34.29% | |
| GB:TCF | Evgen Pharma | 0.17 | -0.04 | -19.05% | |
| GB:FUM | Futura Medical | 0.19 | -2.13 | -91.81% | |
| GB:NFX | Nuformix Plc | 0.10 | -0.27 | -72.97% | |
| GB:OPTI | OptiBiotix Health | 5.60 | -2.15 | -27.74% | |
| GB:VAL | ValiRx plc | 0.16 | -0.07 | -31.91% |
Cizzle Biotechnology Holdings PLC Corporate Events
Cizzle Biotechnology Gains Industry Recognition for Early Lung Cancer Test
PositiveCizzle Biotechnology Holdings PLC, a UK-based developer of blood-based diagnostics for early cancer detection, is advancing commercialisation of its CIZ1B biomarker test for early-stage lung cancer. The test, built on research into the CIZ1 protein a...
Cizzle Biotechnology Restructures U.S. Royalty Deal as Lung Cancer Test Rollout Accelerates
PositiveCizzle Biotechnology has validated its CIZ1B lung cancer biomarker test in a CLIA-accredited U.S. laboratory and is expanding access through additional partners such as BioBridge Global to build a resilient national testing network. The company suppo...
Cizzle Biotechnology Enters Commercial Phase as U.S. Lung Cancer Test Wins CLIA Approval
PositiveCizzle Biotechnology has transitioned from development to commercialisation after its CIZ1B biomarker blood test for early-stage lung cancer gained CLIA accreditation for clinical use in the U.S., unlocking access to the world’s largest diagnos...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 16, 2026